<?xml version="1.0" ?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" 
 xmlns:mml="http://www.w3.org/1998/Math/MathML">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text>
		<front/>
		<body/>
		<back>
<listBibl>
	<bibl>. <author>Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD</author>. <title level="a">Atopic dermatitis</title>. <title level="j">Nat Rev Dis Primers</title>. <date>2018</date>;<biblScope unit="volume">4</biblScope>(<biblScope unit="issue">1</biblScope>):<biblScope unit="page">1</biblScope>. <idno>doi:10.1038/s41572-018-0001-z</idno></bibl>
	<bibl>. <author>Langan SM, Irvine AD, Weidinger S</author>. <title level="a">Atopic dermatitis</title>. <title level="j">Lancet</title>. <date>2020</date>;<biblScope unit="volume">396</biblScope>(<date>10247</date>):<biblScope unit="page">345-360</biblScope>. <idno>doi:10.1016/S0140-6736(20)31286-1</idno></bibl>
	<bibl>. <author>Howell MD, Kuo FI, Smith PA</author>. <title level="a">Targeting the Janus kinase family in autoimmune skin diseases</title>. <title level="j">Front Immunol.</title> <date>2019</date>;<biblScope unit="volume">10</biblScope>:<biblScope unit="page">2342</biblScope>. <idno>doi:10.3389/ fimmu.2019.02342</idno></bibl>
	<bibl>. <author>He H, Guttman-Yassky E</author>. <title level="a">JAK inhibitors for atopic dermatitis: an update</title>. <title level="j">Am J Clin Dermatol</title>. <date>2019</date>;<biblScope unit="volume">20</biblScope>(<biblScope unit="issue">2</biblScope>):<biblScope unit="page">181-192</biblScope>. <idno>doi:10.1007/ s40257-018-0413-2</idno></bibl>
	<bibl>. <author>Simpson EL, Bieber T, Guttman-Yassky E, et al</author>; <title level="a">SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis</title>. <title level="j">N Engl J Med</title>. <date>2016</date>;<biblScope unit="volume">375</biblScope>(<biblScope unit="issue">24</biblScope>):<biblScope unit="page">2335-2348</biblScope>. <idno>doi:10. 1056/NEJMoa1610020</idno></bibl>
	<bibl>. <author>Parmentier JM, Voss J, Graff C, et al.</author> <title level="a">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</title>. <title level="j">BMC Rheumatol</title>. <date>2018</date>;<biblScope unit="volume">2</biblScope>:<biblScope unit="page">23</biblScope>. <idno>doi:10.1186/s41927-018-0031-x</idno></bibl>
	<bibl>. <author>Guttman-Yassky E, Thaçi D, Pangan AL, et al.</author> <title level="a">Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial</title>. <title level="j">J Allergy Clin Immunol</title>. <date>2020</date>;<biblScope unit="volume">145</biblScope>(<biblScope unit="issue">3</biblScope>):<biblScope unit="page">877-884</biblScope>. <idno>doi:10.1016/ j.jaci.2019.11.025</idno></bibl>
	<bibl>. <author>Guttman-Yassky E, Teixeira HD, Simpson EL, et al.</author> <title level="a">Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials</title>. <title level="j">Lancet</title>. <date>2021</date>; <biblScope unit="volume">397</biblScope>(<date>10290</date>):<biblScope unit="page">2151-2168</biblScope>. <idno>doi:10.1016/ S0140-6736(21)00588-2</idno></bibl>
	<bibl>. <author>Reich K, Teixeira HD, de Bruin-Weller M, et al.</author> <title level="a">Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial</title>. <title level="j">Lancet</title>. <date>2021</date>;<biblScope unit="volume">397</biblScope> (<date>10290</date>):<biblScope unit="page">2169-2181</biblScope>. <idno>doi:10.1016/ S0140-6736(21)00589-4</idno></bibl>
	<bibl>. <title level="j">World Medical Association</title>. <title level="a">World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects</title>. <title level="j">JAMA</title>. <date>2013</date>;<biblScope unit="volume">310</biblScope>(<biblScope unit="issue">20</biblScope>):<biblScope unit="page">2191-2194</biblScope>. <idno>doi:10. 1001/jama.2013.281053</idno></bibl>
	<bibl>. <author>Hanifin JM, Rajka G</author>. <title level="a">Diagnostic features of atopic dermatitis</title>. <title level="j">Acta Dermatovener (Stockholm)</title>. <date>1980</date>;<biblScope unit="volume">60</biblScope>(<biblScope unit="issue">92</biblScope>):<biblScope unit="page">44-47</biblScope>.</bibl>
	<bibl>. <author>Silverberg JI, Lei D, Yousaf M, et al.</author> <title level="a">What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? a prospective observational study</title>. <title level="j">Br J Dermatol</title>. <date>2021</date>;<biblScope unit="volume">184</biblScope>(<biblScope unit="issue">5</biblScope>):<biblScope unit="page">888-895</biblScope>. <idno>doi:10.1111/bjd.19457</idno></bibl>
	<bibl>. <author>Schmitt J, Csötönyi F, Bauer A, Meurer M</author>. <title level="a">Determinants of treatment goals and satisfaction of patients with atopic eczema</title>. <title level="j">J Dtsch Dermatol Ges</title>. <date>2008</date>;<biblScope unit="volume">6</biblScope>(<biblScope unit="issue">6</biblScope>):<biblScope unit="page">458-465</biblScope>. <idno>doi:10.1111/j.1610-0387.2007. 06609.x</idno></bibl>
	<bibl>. <author>Silverberg JI, Kantor RW, Dalal P, et al.</author> <title level="a">A comprehensive conceptual model of the experience of chronic itch in adults</title>. <title level="j">Am J Clin Dermatol</title>. <date>2018</date>;<biblScope unit="volume">19</biblScope>(<biblScope unit="issue">5</biblScope>):<biblScope unit="page">759-769</biblScope>. <idno>doi:10.1007/s40257-018-0381-6</idno></bibl>
	<bibl>. <author>Augustin M, Langenbruch A, Blome C, et al.</author> <title level="a">Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation</title>. <title level="j">J Eur Acad Dermatol Venereol</title>. <date>2020</date>;<biblScope unit="volume">34</biblScope> (<biblScope unit="issue">1</biblScope>):<biblScope unit="page">142-152</biblScope>. <idno>doi:10.1111/jdv.15919</idno></bibl>
	<bibl>. <author>Leung DY, Guttman-Yassky E</author>. <title level="a">Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches</title>. <title level="j">J Allergy Clin Immunol</title>. <date>2014</date>;<biblScope unit="volume">134</biblScope>(<biblScope unit="issue">4</biblScope>):<biblScope unit="page">769-779</biblScope>. <idno>doi:10.1016/j.jaci. 2014.08.008</idno></bibl>
	<bibl>. <author>Silverberg JI, Simpson EL, Thyssen JP, et al.</author> <title level="a">Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial</title>. <title level="j">JAMA Dermatol</title>. <date>2020</date>;<biblScope unit="volume">156</biblScope>(<biblScope unit="issue">8</biblScope>):<biblScope unit="page">863-873</biblScope>. <idno>doi:10.1001/ jamadermatol.2020.1406</idno></bibl>
	<bibl>. <author>Simpson EL, Sinclair R, Forman S, et al.</author> <title level="a">Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial</title>. <title level="j">Lancet</title>. <date>2020</date>;<biblScope unit="volume">396</biblScope> (<date>10246</date>):<biblScope unit="page">255-266</biblScope>. <idno>doi:10.1016/ S0140-6736</idno>(<biblScope unit="volume">20</biblScope>)<biblScope unit="page">30732-7</biblScope></bibl>
	<bibl>. <author>Simpson EL, Lacour JP, Spelman L, et al.</author> <title level="a">Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials</title>. <title level="j">Br J Dermatol</title>. <date>2020</date>;<biblScope unit="volume">183</biblScope>(<biblScope unit="issue">2</biblScope>):<biblScope unit="page">242-255</biblScope>. <idno>doi:10.1111/ bjd.18898</idno></bibl>
	<bibl>. <author>Eichenfield LF, Tom WL, Berger TG, et al.</author> <title level="a">Guidelines of care for the management of atopic dermatitis, section 2: management and treatment of atopic dermatitis with topical therapies</title>. <title level="j">J Am Acad Dermatol</title>. <date>2014</date>;<biblScope unit="volume">71</biblScope>(<biblScope unit="issue">1</biblScope>):<biblScope unit="page">116-132</biblScope>. <idno>doi:10.1016/j. jaad.2014.03.023</idno></bibl>

		</listBibl>
	</back>
	</text>
</TEI>
